GenomeQuest's genomic decision support system achieves HIPAA compliance

GenomeQuest Inc., a global provider of large-scale genomic software applications, today announced that its GQ-Dx genomic decision support system for the production of clinical-grade diagnostic reports from next-generation sequencing (NGS) runs now meets Health Insurance Portability and Accountability Act (HIPAA) security and privacy standards. HIPAA rules protect the privacy of individually identifiable health information and set national standards for the security of electronic health information. Following the successful completion of an independent audit, GQ-Dx is the first HIPAA-compliant genomic decision support system for the production of diagnostic reports.

“Ensuring the security and privacy of sensitive patient data is a critical concern for the forward-thinking organizations introducing lab-developed NGS diagnostics to the clinic. As the first company to offer a HIPAA-compliant genomic decision support system, GenomeQuest is helping these innovators advance clinical NGS with confidence”

"Ensuring the security and privacy of sensitive patient data is a critical concern for the forward-thinking organizations introducing lab-developed NGS diagnostics to the clinic. As the first company to offer a HIPAA-compliant genomic decision support system, GenomeQuest is helping these innovators advance clinical NGS with confidence," said GenomeQuest CEO Richard Resnick. "The evolution of NGS from research to the clinic requires more than retooling research applications; it requires a thorough approach that recasts interpretation and annotation capabilities to meet healthcare industry standards and regulatory requirements."

Beginning today, all GQ-Dx deployments, as well as all GenomeQuest research applications, are HIPAA-compliant.